Log in to search using one of your social media accounts:

 

AXIM Biotechnologies secures approval in Netherlands for IBS trial for CBD product
AXIM Biotechnologies has secured approval from the Medical Ethical Committee (METC) of Wageningen University in the Netherlands to commence a trial on patients suffering from irritable bowel syndrome (IBS) with its product CanChew Plus CBD-containing … (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news

Myeloma XI ’s Phase III trial result shows increase in myeloma patient remission
Myeloma XI has reported that the Phase III trial conducted in myeloma has indicated a 95% increase in progression-free survival (PFS) in myeloma patients receiving lenalidomide maintenance treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news

Mast Therapeutics begins enrolment for Phase II INABLE-TRAINING study of AIR001 to treat HFpEF
US-based biopharmaceutical company Mast Therapeutics has begun enrolment for its Phase II INABLE-TRAINING study of AIR001 to treat heart failure with preserved ejection fraction (HFpEF). (Source: Drug Development Technology)
Source: Drug Development Technology - December 8, 2016 Category: Pharmaceuticals Source Type: news

Noveome begins Phase II trial of ST266 to treat allergic conjunctivitis
US-based clinical stage biotherapeutics company Noveome has begun its Phase II clinical trial of ST266 to treat allergic conjunctivitis. (Source: Drug Development Technology)
Source: Drug Development Technology - December 7, 2016 Category: Pharmaceuticals Source Type: news

G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib
US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy. (Source: Drug Development Technology)
Source: Drug Development Technology - December 7, 2016 Category: Pharmaceuticals Source Type: news

TherapeuticsMD reports Phase III Replenish Trial positive top-line data of TX-001HR to treat VMS
US-based healthcare company TherapeuticsMD has reported positive top-line results of its pivotal Phase III Replenish Trial of TX-001HR to treat moderate-to-severe vasomotor symptoms (VMS) due to menopause in post-menopausal women with an intact uteru … (Source: Drug Development Technology)
Source: Drug Development Technology - December 7, 2016 Category: Pharmaceuticals Source Type: news

November ’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial
UK ’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November. (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

Janssen-Cilag reports long-term follow-up data from Phase III RESONATE-2 trial of Ibrutinib to treat CLL
Janssen-Cilag has reported positive long-term follow-up results from its Phase III RESONATE-2 trial of Ibrutinib to treat chronic lymphocytic leukaemia (CLL). (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

Novartis reports positive Phase II SUSTAIN study results of SEG101 to treat SCPC
Novartis has reported positive data from its Phase II SUSTAIN study of SEG101 (crizanlizumab) to treat sickle-cell-related pain crises (SCPC). (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

CSL Behring reports positive Phase III PROLONG-9FP trial data of IDELVION to treat haemophilia B
Australian CSL's US biotherapeutics subsidiary CSL Behring has reported positive results from its Phase III PROLONG-9FP clinical development programme of IDELVION to treat haemophilia B. (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

Malvern Hosts Webinar on Optimising Gel Permeation Chromotography (GPC) Measurements by Combining High-Performance Columns and Powerful Advanced Detectors
Malvern has announced it will be hosting a webinar discussing gel permeation chromatography (GPC). (Source: Drug Development Technology)
Source: Drug Development Technology - December 5, 2016 Category: Pharmaceuticals Source Type: news

Basilea expands ongoing Phase I/IIa clinical trial of BAL101553 to include glioblastoma patients
Swiss biopharmaceutical company Basilea has expanded its ongoing Phase I/IIa clinical trial of BAL101553 to include adult patients with recurrent or progressive glioblastoma. (Source: Drug Development Technology)
Source: Drug Development Technology - December 5, 2016 Category: Pharmaceuticals Source Type: news

Cytokinetics initiates Phase III trial of omecamtiv mecarbil to treat chronic heart failure
US-based late-stage biopharmaceutical company Cytokinetics has initiated its Phase III GALACTIC-HF clinical trial of omecamtiv mecarbil to treat patients experiencing chronic heart failure. (Source: Drug Development Technology)
Source: Drug Development Technology - December 5, 2016 Category: Pharmaceuticals Source Type: news

Western University to initiate Phase II human trial of HIV vaccine
The research team at Western University ’s Schulich School of Medicine& Dentistry are planning to put their HIV vaccine (SAV001) into Phase II human clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - December 5, 2016 Category: Pharmaceuticals Source Type: news

Deals this week: Teva Pharma, Boston Children ’s Hospital, MedImmune
Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in Israel. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2016 Category: Pharmaceuticals Source Type: news

Novan reports positive top-line data from Phase II clinical trial of SB206 against HPV
US-based pharmaceutical company Novan has reported positive top-line results from its Phase II clinical trial of SB206 to treat genital warts caused by human papillomavirus (HPV). (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2016 Category: Pharmaceuticals Source Type: news

New study reveals hallucinogenic drug psilocybin reduces cancer patients' distress
A new study conducted by NYU Langone Medical Center researchers has revealed that a single dose of hallucinogenic drug psilocybin relieves anxiety and depression in patients with advanced cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2016 Category: Pharmaceuticals Source Type: news

M & As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent
Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan, China. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2016 Category: Pharmaceuticals Source Type: news

MicuRx begins Phase I trial of MRX-4 against Gram-positive bacteria
US-based biopharmaceutical company MicuRx has begun its Phase I clinical trial of MRX-4, for the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE). (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2016 Category: Pharmaceuticals Source Type: news

Xultophy 100/3.6 for the Treatment of Type 2 Diabetes
Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2016 Category: Pharmaceuticals Source Type: news

Cerecor ’s Phase II clinical trial of CERC-301 to treat MDD fails to meet primary endpoint
US-based clinical-stage biopharmaceutical company Cerecor has reported that its Phase II clinical trial of CERC-301 to treat major depressive disorder (MDD) has failed to meet its primary endpoint. (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2016 Category: Pharmaceuticals Source Type: news

Innate Pharma reports positive Phase I/II trial data of monalizumab for advanced gynecologic malignancies
French clinical-stage biotechnology company Innate Pharma has reported positive data from its dose-ranging part of a Phase I/II trial of monalizumab to treat advanced gynecologic malignancies. (Source: Drug Development Technology)
Source: Drug Development Technology - December 1, 2016 Category: Pharmaceuticals Source Type: news

Santen reports positive top-line data from SAKURA programme of OPSIRIA to treat uveitis
Japanese specialty ophthalmology company Santen Pharmaceutical has reported positive topline results from its SAKURA clinical development programme of OPSIRIA (440 µ g sirolimus injection) to treat non-infectious uveitis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 30, 2016 Category: Pharmaceuticals Source Type: news

NIAID-funded clinical trial to evaluate shorter-duration antibiotics in children
Five medical centres in the US are planning to conduct the SCOUT-CAP clinical trial to determine the efficacy of shorter course of antibiotics in treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of … (Source: Drug Development Technology)
Source: Drug Development Technology - November 30, 2016 Category: Pharmaceuticals Source Type: news

Sensorion to begin Phase II clinical trial of SENS-111 to treat vertigo
French biotech company Sensorion is set to begin its Phase II clinical trial of SENS-111 to treat acute severe vertigo. (Source: Drug Development Technology)
Source: Drug Development Technology - November 30, 2016 Category: Pharmaceuticals Source Type: news

Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn ’s Disease
Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

PharmaMar initiates Phase I study of PM1183 to treat patients with solid tumours in Japan
PharmaMar has initiated its Phase I study of PM1183 (lurbinectedin) to treat patients with certain types of unresectable / advanced solid tumours in Japan. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa
The National Institute of Allergy and Infectious Diseases (NIAID) is set to initiate a new research study, HVTN 702, of a new HIV vaccine in South Africa. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

Janssen begins Phase IIb study of drug combination to treat hepatitis C virus infection
Janssen Research& Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 29, 2016 Category: Pharmaceuticals Source Type: news

Adimmune continues patient enrolment for Phase III trial of Quadrivalent Influenza Vaccine
Asian flu vaccine provider Adimmune is continuing with patient enrolment for its Phase III trial of Quadrivalent Influenza Vaccine in Europe. (Source: Drug Development Technology)
Source: Drug Development Technology - November 28, 2016 Category: Pharmaceuticals Source Type: news

MindMetre report advocates prioritisation and better funding of pathology services
UK-based consumer and business analyst MindMetre has released a new report highlighting return-on-investment from pathology services in the National Health Service (NHS) and advocating against consolidation of pathology laboratories. (Source: Drug Development Technology)
Source: Drug Development Technology - November 28, 2016 Category: Pharmaceuticals Source Type: news

GSK initiates Phase III programme of daprodustat
UK drug manufacturer GlaxoSmithKline (GSK) has initiated its Phase III programme of daprodustat being developed to treat anaemia associated with chronic kidney disease (CKD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 28, 2016 Category: Pharmaceuticals Source Type: news

M & As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici
Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of $125m. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

Report: Psoriatic arthritis market to reach $12.6bn by 2025
The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by GlobalData. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

Deals this week: Rosetta Genomics, Enamine, Wuxi Biologics
Rosetta Genomics and Sheba Medical Centre have entered a research agreement to develop and evaluate the efficacy of microRNA biomarkers to analyse the response of the drug nivolumab in lung cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

Bavarian Nordic closes enrolment for Phase III study of smallpox vaccines
Biopharmaceutical firm Bavarian Nordic has completed enrolment for its Phase III study of smallpox vaccines, IMVAMUNE and ACAM2000. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

Juno Therapeutics halts Phase III ROCKET trial of JCAR015 to treat leukaemia
US-based biopharmaceutical company Juno Therapeutics has halted its Phase III ROCKET trial of JCAR015 to treat adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2016 Category: Pharmaceuticals Source Type: news

Malvern Hosts Webinar Discussing the Analysis of Particulates in Injectable Drugs
Malvern has announced its latest webinar discussing the types of technologies used for analysing particulates in injectable drugs. (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Galapagos begins DIVERSITY Phase III study of filgotinib to treat Crohn ’s disease
Belgium-based clinical-stage biotechnology company Galapagos has begun its DIVERSITY Phase III study of filgotinib to treat Crohn ’s disease (CD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Eli Lilly and Company ’s Phase III EXPEDITION3 trial of solanezumab fails to meet primary endpoint
Eli Lilly and Company has reported that its Phase III EXPEDITION3 clinical trial of solanezumab failed to meet its primary endpoint in treating people with mild dementia due to Alzheimer's disease (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Neurotrope closes patient enrolment for Phase II study of bryostatin to treat AD
US-based biotechnology company Neurotrope has completed enrolment for its Phase II study of bryostatin to treat moderate-to-severe Alzheimer's disease (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Diurnal begins Phase I trial of DITEST to treat hypogonadism
UK-based specialist pharmaceutical company Diurnal has begun its Phase I clinical trial of DITEST to treat males with hypogonadism. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2016 Category: Pharmaceuticals Source Type: news

Yisheng Biopharma completes Phase I clinical trial of PIKA hepatitis B vaccine
Chinese biopharmaceutical company Yisheng Biopharma has completed its Phase I clinical trial of PIKA hepatitis B vaccine to provide prophylactic and therapeutic benefits against hepatitis B virus infection. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2016 Category: Pharmaceuticals Source Type: news

Washington University and Harvard Medical School report positive topical immunotherapy trial results
The Washington University School of Medicine in St. Louis and Harvard Medical School have reported positive results from a clinical study of combination of two topical drugs, cream formulation of topical 5-fluorouracil and calcipotriol, to treat earl … (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2016 Category: Pharmaceuticals Source Type: news

Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection
Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment. (Source: Drug Development Technology)
Source: Drug Development Technology - November 22, 2016 Category: Pharmaceuticals Source Type: news

Celyad receives approval to begin THINK clinical trial of NKR-2 product in Belgium to treat cancer
Belgium-based clinical-stage biopharmaceutical company Celyad has received approval in Belgium to begin the Therapeutic Immunotherapy with NKR-2 (THINK) clinical trial of NKR-2 product to treat seven cancer indications, including both solid and hemat … (Source: Drug Development Technology)
Source: Drug Development Technology - November 22, 2016 Category: Pharmaceuticals Source Type: news

Tenax completes enrolment for Phase III cardiac surgery trial of levosimendan
US-based specialty pharmaceutical company Tenax has completed patient enrolment in its Phase III LEVO-CTS trial of Levosimendan to be used during cardiac surgery. (Source: Drug Development Technology)
Source: Drug Development Technology - November 22, 2016 Category: Pharmaceuticals Source Type: news

Athenex and Eli Lilly collaborate for Phase Ib cancer study of combination drug
Athenex and Eli Lilly have collaborated to conduct a Phase Ib study of oraxol and cyramza (ramucirumab) to treat patients with advanced gastric (stomach) and esophageal cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - November 22, 2016 Category: Pharmaceuticals Source Type: news

Dermata Therapeutics commences treatment in Phase 2 atopic dermatitis study
Biotechnology company Dermata Therapeutics has announced the dosing of its first patient in a Phase 2 atopic dermatitis study with its lead compound DMT210. (Source: Drug Development Technology)
Source: Drug Development Technology - November 21, 2016 Category: Pharmaceuticals Source Type: news